Fulcrum Therapeutics Stock News

CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference, on Thursday, February 17, 2022 at 9:20 a.m. ET.

The Phase 1b trial for the drug remains on track and will be initiated soon.

CAMBRIDGE, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (NASDAQ: FULC ), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that Bryan Stuart, President and Chief Executive Officer, will present at the virtual 40 th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 12:00 p.m. Full story available on Benzinga.com

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) was the recipient of a large decline in short interest in the month of November. As of November 30th, there was short interest totalling 2,090,000 shares, a decline of 31.0% from the November 15th total of 3,030,000 shares. Based on an average daily volume of 531,500 shares, the short-interest ratio is []

Fulcrum Therapeutics Inc (NASDAQ: Full story available on Benzinga.com

Achieved mean 5.6-fold HBG mRNA induction at 20mg and mean 6.2-fold at 30mg after 14 days of once-daily dosing, further supporting potential of FTX-6058 to provide a functional cure

Fulcrum Therapeutics Inc (NASDAQ: FULC) has announced results from the 20mg and 30mg dose cohorts in healthy adult volunteers in its Phase 1 trial of FTX-6058 for sickle cell disease and other hemo

Fulcrum Therapeutics (NASDAQ:FULC) and Sycamore Entertainment Group (OTCMKTS:SEGI) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, analyst recommendations and institutional ownership. Insider & Institutional Ownership 78.8% of Fulcrum Therapeutics shares are held by institutional investors. 22.3% []

Charles Schwab Investment Management Inc. lifted its position in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) by 24.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 54,284 shares of the companys stock after purchasing an additional 10,654 shares during the quarter. Charles Schwab Investment []

Fulcrum Therapeutics Inc. (NASDAQ:FULC) shares, rose in value on Wednesday, 11/24/21, with the stock price up by 1.33% to the previous days close as strong demand from buyers drove the stock to $15.21. Actively observing the price movement in the last trading, the stock closed the session at $15.01, falling within a range of $14.55 Metrics That Matter About Fulcrum Therapeutics Inc. (NASDAQ: FULC) Read More »

Related Stocks: COGT , CERS , NXTC , IMTX , CLDX , MCRB , FULC , ARVN , LPTX , ERAS , CYTK , LHDX , DRNA , RNLX , KDNY , MGNX , VSTM , TCRR , ALDX , CGEM ,

Fulcrum Therapeutics, Inc. (FULC) CEO Bryan Stuart on Q3 2021 results - Earnings Call Transcript

Fulcrum Therapeutics, Inc. (FULC) delivered earnings and revenue surprises of 10.94% and 68.03%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for th

CAMBRIDGE, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.  (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically

CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.  (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically